BioCryst Pharmaceuticals To Present Four Abstracts From Second Interim Analysis of APeX-P Trial At Annual Scientific Meeting Of The American College Of Allergy, Asthma & Immunology In Orlando, Florida

Author: Benzinga Newsdesk | October 23, 2025 06:03am

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years as well as findings on the psychosocial impact of HAE on young patients and their caregivers.

Posted In: BCRX